About Us
Executive Director, Chief Executive Officer: Mr. Eric Tse
-
- Executive Director, Chief Executive Officer: Mr. Eric Tse
- He has served as an Executive Director of Sino Biopharmaceutical Limited since 2019, Chairman of CTTQ Pharma since 2020, and has been the Chief Executive Officer of Sino Biopharmaceutical Limited and Chairman of Beijing Tide Pharmaceutical Co., Ltd. since 2022. He holds a Bachelor's degree in Economics from the Wharton School of the University of Pennsylvania, a Master's degree in Management from Schwarzman College at Tsinghua University, and is a Ph.D. candidate in Social and Administrative Pharmacy at China Pharmaceutical University. He was awarded the "Top 10 Outstanding Chinese American Youth" and "Advanced Individual for Outstanding Contribution to Jiangsu Manufacturing".
Mr. Eric Tse is currently a member of the Beijing Municipal Committee of the CPPCC, a member of the 14th National Committee of the All-China Youth Federation, Vice Chairman of the 13th Committee of the Shaanxi Youth Federation, a member of the 7th Election Committee of the Hong Kong SAR, Vice President of the Hong Kong CPPCC Youth Association, a member of the Digital Economy Committee of the APEC China Business Council, a member of the Presidium of Global Shapers under the World Economic Forum, Vice Chairman of the Science and Technology Innovation Committee of the Belt and Road General Chamber of Commerce, a member of the Y.Elites Association, and Executive Vice President of the Jiangsu Overseas Chinese Entrepreneurs Association.
Since taking over as Chief Executive Officer of Sino Biopharmaceutical, Mr. Eric Tse has focused on the four major strategies of "organizational integration, comprehensive innovation, internationalization, and digitalization". He oversees the Group's daily operations, advances major decisions on corporate strategy, personnel appointments, and investment integration, and comprehensively manages the Group's subsidiary member companies. He is building a professional management team to further enhance organizational efficiency, drive innovative business, link external cooperation, and advance the Group's global innovation process, committed to building an international innovative pharmaceutical company of China.
Mr. Eric Tse leads the company in unswervingly following the path of innovation and transformation, and building long-term core competitive advantages through comprehensive innovation. Sino Biopharmaceutical and its subsidiaries, such as Chia Tai Tianqing Pharmaceutical Group Co., Ltd. and Beijing Tide Pharmaceutical Co., Ltd., uphold the mission of "improving the quality and protecting the dignity of human life". Guided by societal clinical medication needs, they focus on the four major areas of oncology, hepatology/cardiometabolic diseases, respiratory/autoimmune diseases, and surgery/analgesia. They advance internal innovation and business development in parallel, cultivate a new innovation ecosystem, shape world-leading innovative R&D capabilities, enhance the Group's core competitiveness with new quality productive forces, and continuously achieve outstanding accomplishments and innovative breakthroughs.
Under the leadership of Eric Tse, the proportion of R&D investment in innovative drugs at Sino Biopharmaceutical has increased to over 80% of total R&D spending. The Company has proactively invested in multiple new targets, new platforms, and new technologies with blockbuster potential. In the next three years, 20 innovative products/new indications are expected to be launched to serve patients. Leveraging the strong platform of Sino Biopharmaceutical, its subsidiaries Chia Tai Tianqing and Beijing Tide Pharmaceutical have developed steadily. For many consecutive years, they have been selected for authoritative industry lists such as the Top 100 Pharmaceutical Companies in China and the Best Industrial Enterprises for Pharmaceutical R&D Pipelines in China. They have undertaken more than 80 national and provincial science and technology projects and have received honors such as the "China Patent Gold Award" and the "National Science and Technology Progress Award".
While dedicated to corporate management, Mr. Eric Tse is passionate about and actively involved in youth work in Hong Kong and the Guangdong-Hong-Kong-Macao Greater Bay Area. He frequently speaks out in the Hong Kong media on important topics such as Hong Kong's integration into the national development strategy, the steady and long-term implementation of "One Country, Two Systems", and promoting Hong Kong's transition "from order to prosperity", contributing to the long-term prosperity, stability, and continued brilliance of Hong Kong.
*Portrait rights belong to the individual. Unauthorized use is prohibited.
-
Breaking Through in International Multicenter Clinical Mutual Recognition, "R&D Without Borders · Sino Biopharmaceutical Sets Sail" International Biopharmaceutical Innovation and Development Forum Held in Shanghai 2026.06
On June 6, the "R&D Without Borders · Sino Biopharmaceutical Sets Sail" International Biopharmaceutical Innovation and Development Forum was held at the Chia Tai Tianqing Global R&D Headquarters in Minhang District, Shanghai.View > -
100 Million Yuan Donation! Chia Tai Tianqing Partners with China Science and Technology Development Foundation to Co-create a Biopharmaceutical Innovation Ecosystem 2026.05
On May 22, Chia Tai Tianqing Pharmaceutical Group, a core enterprise of Sino Biopharmaceutical (1177.HK), donated 100 million yuan to the China Science and Technology Development Foundation. This move actively implements the national "15th Five-Year Plan" strategic layout, helps build the biopharmaceutical industry into a national emerging pillar industry, and empowers the nation's high-level scientific and technological self-reliance with concrete actions.View > -
Major News! Hernexeos® First-Line Indication Approved in China, Becoming the Country's First-Line Targeted Therapy for HER2-Mutant Lung Cancer 2026.05
On May 21, Sino Biopharmaceutical (1177.HK) and Boehringer Ingelheim jointly announced that Hernexeos® (generic name in Chinese: zongertinib tablets, generic name in English: zongertinib), which they are co-promoting in mainland China, has been approved by the China National Medical Products Administration (NMPA).View > -
Sino Biopharm and GlaxoSmithKline Forge Exclusive Strategic Partnership to Advance the World's First Blockbuster Drug for Curing Hepatitis B 2026.05
On May 11, Sino Biopharm (1177.HK) officially announced that its core enterprise, Chia Tai Tianqing, has entered into an exclusive strategic partnership with GlaxoSmithKline (GSK) to accelerate the marketing process of the first-in-class (FIC) new drug Bepirovirsen in China. Earlier this year, a marketing application for Bepirovirsen was submitted to the Center for Drug Evaluation (CDE) of the National Medical Products Administration and was included in the priority review list.View > -
Cheng Cheung Ling and Eric Tse Attend the Inaugural Hong Kong Embodied AI Industry Summit, Ushering in a New Era of Embodied AI Productivity 2026.05
On May 12, the inaugural Hong Kong Embodied AI Industry Summit, co-initiated by the Hong Kong Federation of Overseas Chinese Associations and AgileX Robotics, opened in Hong Kong. John Lee Ka-chiu, Chief Executive of the Hong Kong Special Administrative Region; Frederick Ma Si-hang, Chairman of the Hong Kong Trade Development Council; Cheng Cheung Ling, President of Chia Tai Pharmaceutical Group and President of the Hong Kong Federation of Overseas Chinese Associations, attended the event and delivered speeches.View > -
Xu Xiao, First Secretary of the Secretariat of the Central Committee of the Communist Youth League, Leads Delegation to Inspect Chia Tai Tianqing, Focusing on Innovative Development and Youth Talent Cultivation 2026.04
On the morning of April 25, a delegation led by Xu Xiao, First Secretary of the Secretariat of the Central Committee of the Communist Youth League and Chairman of the All-China Youth Federation, visited CTTQ, a core enterprise of Sino Biopharmaceutical (1177.HK), for inspection and guidance.View > -
Jointly Promoting New Development in China-UAE Economic and Trade Cooperation! China-UAE Business and Investment Promotion Conference Held in Beijing, Eric Tse Invited to Attend the Opening Ceremony 2026.04
On April 13, the "China-UAE Business and Investment Promotion Conference", jointly hosted by the Ministry of Commerce of the People's Republic of China and the Ministry of Foreign Trade of the United Arab Emirates, was held in Beijing.View > -
Putting the "Patriotism and Love for Hong Kong" Initiative into Practice, the "Mong Kok Community Living Room" Funded by Cheng Cheung Ling Officially Opens 2026.03
On the morning of March 30, the "Mong Kok Community Living Room," sponsored by a donation from Ms. Cheng Cheung Ling, President of the Hong Kong Chinese Friendship Association, President of Chia Tai Pharmaceutical Group, and Vice Chair of the Board of Directors of Sino Biopharmaceutical (1177.HK), officially opened. This marks another important addition to the HKSAR Government's "Community Living Room Pilot Scheme," bringing warm care and tangible support to grassroots families in the Yau Tsim Mong District.View > -
Sino Biopharm Releases 2025 Annual Results: Revenue and Net Profit Maintain Double-Digit Growth, Innovative Product Revenue Exceeds RMB 15 Billion 2026.03
On March 26, Sino Biopharm (1177.HK) released its 2025 annual results. Driven by the in-depth advancement of its comprehensive innovation and development strategy and the rapid volume growth of innovative products launched intensively over the past three years, the company has delivered impressive results of double-digit growth in both revenue and net profit for four consecutive reporting periods.View > -
Eric Tse Attends Yabuli Entrepreneurs Forum: Breaking the Boundaries of Perception, Technology, and Cooperation to Explore the Path of Innovation and Establishment for Chinese Pharmaceutical Companies 2026.03
On March 17, the 2026 Yabuli Entrepreneurs Forum was held in Yabuli, Heilongjiang. With the theme Confidence, Opportunity, and a New Chapter, the forum brought together entrepreneurs from all sectors to discuss new paths for development.View >